A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)

被引：13
|
作者：
Slomovitz, B. M.
Lu, K. H.
Johnston, T.
Munsell, M.
Ramondetta, L. M.
Broaddus, R. R.
Coleman, R. L.
Walker, C.
Gershenson, D. M.
Burke, T. W.
Wolf, J.
机构：
[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5502
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The mammalian target of rapamycin inhibitor RAD001 (everolimus) in postmenopausal women with early breast cancer: results of a phase II pre-operative trial.
    Macaskill, E. J.
    Bartlett, J. M. S.
    White, S.
    Renshaw, L.
    Campbell, F. M.
    Young, O.
    Stumm, M.
    Faratian, D.
    Thomas, J. S.
    Barber, M. D.
    Dixon, J. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S286 - S287
  • [22] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics
    Awada, Ahmad
    Cardoso, Fatima
    Fontaine, Christel
    Dirix, Luc
    De Greve, Jacques
    Sotiriou, Christos
    Steinseifer, Jutta
    Wouters, Carine
    Tanaka, Chiaki
    Zoellner, Ulrike
    Tang, Pui
    Piccart, Martine
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 84 - 91
  • [23] Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurrent endometrial cancer: Translational evaluation from a phase II study
    Slomovitz, Brian M.
    Burke, Thomas
    Lu, Karen H.
    Wolf, Judith
    Johnston, Taren
    Wu, Weiguo
    Celestino, Joseph
    Schmeler, Kathleen
    Soliman, Pamela
    Broaddus, Russell
    Walker, Cheryl
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : S30 - S31
  • [24] A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-hodgkin lymphoma (NHL)
    Gornet, Michel K.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Micallef, Ivana N.
    Porrata, Luis F.
    Johnston, Patrick B.
    Maurer, Matthew J.
    LaPlant, Betsy
    Kabat, Brian
    Inwards, David J.
    Colgan, Joseph P.
    Call, Timothy
    Markovic, Svetomir
    Zent, Clive S.
    Zeldenrust, Steven R.
    Tun, Han W.
    Witzig, Thomas E.
    BLOOD, 2007, 110 (11) : 44A - 44A
  • [25] Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer
    Johnson, Bruce E.
    Jackman, David
    Janne, Pasi A.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4628S - 4631S
  • [26] A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy
    Jac, J.
    Amato, R. J.
    Giessinger, S.
    Saxena, S.
    Willis, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Witzig, Thomas E.
    Gertz, Morie
    LaPlant, Betsy
    Hayman, Suzanne
    Camoriano, John
    Lacy, Martha
    Bergsagel, P. Leif
    Chuma, Stacey
    DeAngelo, Daniel
    Treon, Steven P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 237 - 242
  • [28] A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer
    Amato, Robert J.
    Jac, Jaroslaw
    Giessinger, Sarah
    Saxena, Somyata
    Willis, James P.
    CANCER, 2009, 115 (11) : 2438 - 2446
  • [29] Promising results for patients with relapsed or refractory Hodgkin lymphoma treated with the oral mtor inhibitor everolimus (RAD001)
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N. M.
    Porrata, L. F.
    Reeder, C. B.
    Roy, V.
    LaPlant, B. R.
    Witzig, T. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 29 - 29
  • [30] Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)
    Di Cosimo, S
    Matar, P
    Rojo, F
    Guzman, M
    Rodriguez, S
    Jimenez, J
    Arribas, J
    Cognetti, F
    Lane, H
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 213S - 213S
12345